Michael Krel Joins Deinove as Business Development Director
For the three years prior to joining Deinove, Michael Krel served as Business Development Manager at Metabolic Explorer, a green chemistry company specializing in the development of fermentation processes for commodity chemicals. He contributed significantly to implementation of the company's international business activities and, more particularly, in the establishment of Metabolic Explorer's first industrial unit (capacity: 8,000 metric tonnes per year) in Malaysia. While in this post, he was also involved in elaborating Metabolic Explorer's business alliance and collaboration strategy and led negotiations with blue-chip multinationals from the agro resources and chemical industries. He also helped to formalize a number of in-house business processes. From 2005 to 2007, Michael Krel helped to develop the client base at a firm providing strategy and management consultancy. He notably worked as a consultant for some of the leading French multinationals in the energy and materials markets (including Total, Saint Gobain and Suez). Michael Krel holds a first degree in Engineering (class of 1997) and a PhD in Organic Chemistry (2005) from the elite Ecole Polytechnique engineering school in Paris.
"I am very pleased to be joining Deinove's dynamic team of staff. I am looking to make a rapid contribution to the company's international business development efforts - notably by clinching a number of strategic alliances with leading biofuel and chemicals companies", commented Michael Krel.
"We are delighted to welcome Michael to Deinove. His acknowledged business development experience in the greentech sector will boost our commercial and industrial growth", stated Deinove CEO Jacques Biton. "His main role will be to forge collaborations and licensing deals with biofuels and chemicals companies worldwide".
About Deinove
The greentech company Deinove (Alternext Paris: ALDEI) is dedicated to the development and commercial exploitation of innovative technological processes for the production of biofuels and other compounds of industrial or pharmaceutical interest, by exploiting the deinococci's exceptional natural properties. Deinove successfully floated on the Alternext stock market in April 2010. The company intends to leverage its proprietary bacterial strains, technologies and processes by outlicensing to industrial partners. Deinove has partnered with leading sugar, ethanol and starch company TEREOS in order to develop the Deinol project, which aims at producing cellulosic ethanol in existing industrial facilities. Deinove currently has 23 staff and operates several collaborative R&D programmes with the CNRS (Montpellier and Marseilles), the University of Paris V, INSA Toulouse and the VTT in Finland. It was incorporated in late 2006 under the joint impetus of Philippe Pouletty MD (Managing Partner at the private equity firm Truffle Capital) and Professor Miroslav Radman (Professor of Cell Biology at Paris-Descartes University, a member of the French Academy of Science and winner of the 2003 INSERM Medical Research Prize). Professor Radman elucidated the genetic mechanism behind the extraordinary natural properties of the bacterium Deinococcus (biodiversity and robustness) on which Deinove's innovation strategy is based. The company’s headquarters are in Paris and it operates a lab in Montpellier (Cap Alpha technopark), southern France.
For more information, visit www.deinove.com.
Disclaimer: This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in Deinove ("the Company") in any country. This press release contains forward-looking statements that relate to the Company’s objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company’s management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavourable developments in connection with these and other risks and uncertainties described, in particular, in Chapter 4 of the Company’s prospectus prepared in connection with its IPO and on which the French Autorité des Marches Financiers (“AMF”) granted its visa n°. 10-014 on March 25 2010, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
Updates are available on the company's website http://www.deinove.com
Contacts
ALIZE RP Caroline Carmagnol Communication agency Tel.: +33 142 68 86 43 / +33 664 18 99 59 caroline@alizerp.com
DEINOVE Angelita de Francisco Operations and Strategic Marketing Director Tel.: +33 142 03 27 32 / + 33 607 15 28 87 angelita@deinove.com